Cleocin (Clindamycin Hydrochloride)
Compared with: Blackmores Conceive Well Gold 28 Tablets + 28 Capsules

Cleocin (Clindamycin HCl) 150 mg, 300 mg capsules; 75 mg/5 mL oral solution; 150 mg/mL IV solution is a lincosamide antibiotic that reversibly binds the 50S ribosomal subunit to inhibit bacterial protein synthesis. Indicated for serious anaerobic, skin, soft tissue, respiratory, bone, and intra‑abdominal infections—including those due to β‑lactam–resistant organisms—Cleocin offers broad tissue penetration and a well‑characterized safety profile when used as directed
NCBI
Medscape Reference

Clindamycin Hydrochloride – 150 mg, 300 mg capsules; 75 mg/5 mL oral solution; 150 mg/mL injectable solution
FDA Access Data

Clindamycin

Cleocin HCl (capsules)

Cleocin Phosphate (IV solution)

Dalacin C (alternate brand)

Therapeutic Class: Antibiotic

Pharmacologic Class: Lincosamide (50S ribosomal inhibitor)

Legal Category: Prescription Only

Clindamycin binds to the 23S rRNA of the 50S bacterial ribosomal subunit, blocking the peptidyl transferase center. This inhibits peptide‑bond formation and protein synthesis, leading to a primarily bacteriostatic effect that is bactericidal at higher concentrations and depending on organism load
DrugBank
Serious Infections by Anaerobes: Intra‑abdominal abscesses, gynecologic infections

Skin & Soft Tissue Infections: Cellulitis, abscesses, necrotizing fasciitis adjunct

Respiratory Tract Infections: Aspiration pneumonia, lung abscess

Bone & Joint Infections: Osteomyelitis, septic arthritis (IV form)

Intra‑Abdominal Infections: Peritonitis, diverticulitis

Off‑Label: Bacterial vaginosis (topical), acne (topical)
Medical News Today

Indication Oral Dose IV/IM Dose Maximum Daily Dose
Mild-to-Moderate Infections 150–300 mg every 6 hours 600 – 1 200 mg/day divided q6–8h 1.8 g/day
Severe Infections 300 mg every 6 hours 1.2–2.7 g/day divided q6–12h 4.8 g/day
Pediatric (≥1 year) 8–16 mg/kg/day divided q6–8h; severe: 16–25 mg/kg/day divided q6–8h Use clindamycin phosphate solution per weight; divided q6–8h Based on weight—see label
Mayo Clinic
Anthrax (Prophylaxis) 300 mg every 12 hours for 60 days IV not indicated 600 mg/day
Surgical Prophylaxis 900 mg orally or IV 1 hour before incision; redose q6 h if needed 900 mg per dose

Oral Capsules: Take with a full glass of water to avoid esophageal irritation; remain upright ≥30 minutes
FDA Access Data

Oral Solution: Shake well; use calibrated measuring device.

IV Infusion: Infuse over 10–60 minutes; do not mix with aminophylline, phenytoin, or barbiturates in the same solution.

Formulations:

Capsules: 150 mg, 300 mg

Oral Solution: 75 mg/5 mL

IV Solution: 150 mg/mL in single‑dose containers

Route: Oral, IV, IM, topical, intravaginal (formulation‑dependent)

Capsules/oral solution: Room temperature (20–25 °C)

IV solution: 2–8 °C; protect from light

Pregnancy: Category B – No fetal harm in animal studies; use if clearly needed.

Breastfeeding: Excreted in milk; monitor infant for diarrhea or candidiasis.

Pediatric: Approved ≥1 year for oral/IV dosing; use weight‑based dosing.

Elderly: No routine adjustment; higher risk of C. difficile–associated diarrhea.

Renal/Hepatic Impairment: No adjustment, but monitor for toxicity.

Common:

Diarrhea, nausea, vomiting, abdominal pain

Metallic taste, esophagitis

Clostridioides difficile–Associated Diarrhea: May occur up to 6 weeks post‑treatment; discontinue and treat with metronidazole or vancomycin
MSF Medical Guidelines
Hypersensitivity Reactions: Rash, urticaria, anaphylaxis

Blood Dyscrasias: Rare agranulocytosis, thrombocytopenia

Hepatotoxicity: Cholestatic jaundice (rare)

Pseudomembranous Colitis: Boxed warning—monitor for severe diarrhea; discontinue if suspected.

Esophageal Irritation: Take with water and remain upright for 30 minutes post‑dose.

Allergy to Lincosamides: Contraindicated in patients with prior severe reactions to clindamycin or lincomycin.

Neuromuscular Blockade: Use caution in patients receiving neuromuscular blockers; may enhance blockade.

Concomitant Agent Interaction Effect Recommendation
Erythromycin Antagonistic effect on protein synthesis Avoid co‑administration
Neuromuscular Blockers Potentiation of blockade Monitor neuromuscular function
Warfarin ↑Anticoagulant effect (case reports) Monitor INR
Kaolin‐Pectin ↓Absorption Administer ≥3 h before or after

FAQs – Cleocin (Clindamycin)
Q1. How quickly does Cleocin work?
A: Clinical improvement often noted within 48–72 hours; complete full course to prevent resistance.

Q2. Can I take Cleocin with food?
A: Yes; but take capsules with plenty of water and remain upright 30 minutes to minimise esophageal irritation
FDA Access Data

Q3. What if I miss a dose?
A: Take as soon as remembered if >1 hour before next dose; otherwise skip—do not double.

Q4. Is Cleocin safe for children?
A: Yes, ≥1 year with weight‑based dosing under pediatric guidance
Mayo Clinic

Q5. Can Cleocin cause yeast infections?
A: Yes—antibiotic use may predispose to candidiasis; report persistent itching or discharge.

Q6. How should IV Cleocin be administered?
A: Infuse IV over 10–60 minutes; do not exceed recommended concentration; monitor infusion site.

Q7. What if diarrhea develops?
A: Monitor for C. difficile colitis; discontinue and initiate appropriate therapy if severe or bloody.

Cleocin, Clindamycin, Lincosamide Antibiotic, C. difficile Warning, Skin Infection Treatment, Bone Infection Antibiotic, EZ Chemist, Clindamycin Dosage, Clindamycin Side Effects, Lincosamide Mechanism